RxDoctor Payments Data

Caleb Lesnoff, OD

Optometrist · Rocky Mount, NCNPI 1063884575

Payments from drug & device makers

$2,695in general payments, 2019–2025

Across 110 payments — averaging $24.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$832
  • Bausch & Lomb Americas Inc.$326
  • AbbVie$313
  • Sun Pharmaceutical Industries Inc.$212
  • Tarsus Pharmaceuticals, Inc.$164
  • Dompe US, Inc.$151
  • plus $698 from 13 others

What the payments were for

  • Food & beverage$2,695100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,695 in reported general payments places this provider in the 75th percentile of 1,326 optometrist providers in North Carolina.

See all optometrist providers in North Carolina

Medicare billing

Part B allowed, 2024
$212,246
Medicare patients
1,174
Services billed
2,304

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine103$79,569
LumiganBimatoprost178$56,284
RocklatanNetarsudil Mesylat/Latanoprost113$43,590
CombiganBrimonidine Tartrate/Timolol111$30,638
Travoprost152$16,360
SimbrinzaBrinzolamide/Brimonidine Tart70$14,686
VyzultaLatanoprostene Bunod38$12,754
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol105$11,350
Prednisolone Acetate309$10,886
Latanoprost1,112$9,579
Brimonidine Tartrate265$8,176
Alphagan PBrimonidine Tartrate24$6,626
Timolol Maleate352$3,342
Methazolamide23$3,254
Dorzolamide Hcl149$2,908

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$313$173,117416 claims
Aerie Pharmaceuticals, Inc.Rocklatan$30$43,590113 claims
AlconSimbrinza$832$14,68670 claims
Bausch & Lomb Americas Inc.Vyzulta$326$12,75438 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,326 optometrist providers in North Carolina.

Other optometrist in Rocky Mount

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →